Brokerages expect that Oncolytics Biotech, Inc. (NASDAQ:ONCY) will announce earnings of ($0.19) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Oncolytics Biotech’s earnings. Oncolytics Biotech reported earnings of ($0.29) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 34.5%. The business is expected to report its next quarterly earnings results on Friday, March 8th.
On average, analysts expect that Oncolytics Biotech will report full year earnings of ($0.84) per share for the current year, with EPS estimates ranging from ($0.95) to ($0.72). For the next year, analysts forecast that the business will post earnings of ($1.05) per share, with EPS estimates ranging from ($1.24) to ($0.86). Zacks’ EPS averages are an average based on a survey of research analysts that cover Oncolytics Biotech.
Oncolytics Biotech (NASDAQ:ONCY) last announced its quarterly earnings data on Monday, November 12th. The company reported ($0.15) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.04.
ONCY has been the subject of several research analyst reports. ValuEngine cut shares of Oncolytics Biotech from a “buy” rating to a “hold” rating in a report on Thursday, July 26th. LADENBURG THALM/SH SH initiated coverage on shares of Oncolytics Biotech in a report on Monday, October 1st. They issued a “buy” rating for the company. Finally, Royal Bank of Canada restated a “buy” rating on shares of Oncolytics Biotech in a report on Monday, November 12th.
A hedge fund recently bought a new stake in Oncolytics Biotech stock. Millennium Management LLC bought a new stake in Oncolytics Biotech, Inc. (NASDAQ:ONCY) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 489,531 shares of the company’s stock, valued at approximately $2,692,000. Millennium Management LLC owned approximately 2.96% of Oncolytics Biotech at the end of the most recent quarter. Institutional investors own 3.50% of the company’s stock.
Shares of Oncolytics Biotech stock opened at $2.59 on Monday. Oncolytics Biotech has a 12-month low of $2.35 and a 12-month high of $8.55. The firm has a market capitalization of $43.73 million, a PE ratio of -3.04 and a beta of 1.84.
About Oncolytics Biotech
Oncolytics Biotech Inc, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses.
Further Reading: Marijuana Stocks Investing Considerations
Get a free copy of the Zacks research report on Oncolytics Biotech (ONCY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.